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Introduction: Haemophilia B is caused by a deficiency of coagulation factor IX (FIX) and 
characterized by bleeding in muscles and joints. In the perioperative setting, patients 
are treated with FIX replacement therapy to secure haemostasis. Targeting of specified 
FIX levels is challenging and requires frequent monitoring and adjustment of therapy.
Aim: To evaluate perioperative management in haemophilia B, including monitoring 
of FIX infusions and observed FIX levels, whereby predictors of low and high FIX 
levels were assessed.
Methods: In this international multicentre study, haemophilia B patients with 
FIX < 0.05 IU mL−1 undergoing elective, minor or major surgical procedures between 
2000 and 2015 were included. Data were collected on patient, surgical and treat-
ment characteristics. Observed FIX levels were compared to target levels as recom-
mended by guidelines.
Results: A total of 255 surgical procedures were performed in 118 patients (median 
age 40 years, median body weight 79 kg). Sixty percent of FIX levels within 24 hours 
of surgery were below target with a median difference of 0.22 IU mL−1 [IQR 0.12- 
0.36]; while >6 days after surgery, 59% of FIX levels were above target with a median 
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
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1  | INTRODUC TION
Haemophilia B is an X- linked hereditary bleeding disorder character-
ized by a deficiency of coagulation factor IX (FIX). Treatment consists 
of prophylactic or on- demand replacement therapy with recombinant 
or plasma- derived FIX concentrates. However, replacement therapy 
with factor concentrates is costly. In the United Kingdom, 60 million 
international units of FIX concentrates are administered annually in 
663 haemophilia B patients.1 This will most probably increase further 
in the near future, due to the ageing haemophilia patient population 
and necessity of orthopaedic surgery for joint replacement.
In the perioperative setting, patients are generally treated 
with FIX concentrates for 7- 10 consecutive days postoperatively. 
Efficacious perioperative treatment is of importance to prevent 
underdosing with a risk of bleeding and overdosing with a possible 
risk of thrombosis and waste of expensive concentrates. However, 
treatment is complex due to a large interpatient variability, which is 
not taken into account in National guidelines. Recently, we identi-
fied both underdosing and overdosing in perioperative haemophilia 
A patients and the need for optimization of treatment strategies.2 
Collected data were subsequently used to construct a population 
pharmacokinetic (PK) model, currently being validated in a random-
ized controlled trial.3 Few studies have reported on safety and effi-
cacy of perioperative management in haemophilia B.4,5 Therefore, 
studies in these patients are vital to optimize treatment.
To evaluate current perioperative management in severe and 
moderate- severe haemophilia B patients and to identify predictive 
factors of low and high FIX levels, we conducted an international 
multicentre retrospective observational study to collect FIX levels 
after FIX concentrate administration during and after minor and 
major surgery as well as clinical outcome measures (FIX consumption 
and bleeding/thrombotic complications).
2  | METHODS
2.1 | Patients
In this international multicentre retrospective observational cohort 
study, patients were included with severe and moderate haemophilia 
B (FIX <0.05 IU mL−1) who underwent elective minor or major surgical 
procedures with FIX replacement therapy between 1 January 2000 
and 1 December 2015. The procedures were classified by surgical 
risk score as established by Koshy et al.6 Patients attended one of 
ten Haemophilia Treatment Centres in the Netherlands and United 
Kingdom (Erasmus University Medical Centre Rotterdam; Academic 
Medical Centre Amsterdam; University Medical Centre Groningen; 
Leids University Medical Centre Leiden and Radboud university 
medical centre Nijmegen; Great Ormond Street Haemophilia Centre, 
London; Arthur Bloom Haemophilia Centre, Cardiff, Wales; Katharine 
Dormandy Haemophilia Centre, Royal Free London; Churchill Hospital, 
Oxford; The Royal London Hospital, London). Patients received re-
combinant or plasma- derived FIX concentrates to normalize FIX levels. 
Administered recombinant FIX concentrate was BeneFix (Pfizer Wyeth 
Pharmaceuticals Inc., Kent, UK). Plasma- derived FIX concentrates in-
cluded the following: AlphaNine (Grifols Biologicals Inc. Los Angeles, 
USA), Replenine (BPL; Bio Products Laboratory, Hertfordshire, UK), 
Haemonine (Biotest Pharma GmbH, Dreieich, Germany), Mononine 
(CSL Behring GmbH, Marburg, Germany), Nonafact (Sanquin, 
Amsterdam, the Netherlands). Patients with possible disseminated in-
travascular coagulation due to sepsis and patients who developed FIX 
neutralizing antibodies during the perioperative period were excluded. 
The study was not subject to the Medical Research Involving Human 
Subjects Act and was approved by all Medical Ethics Committee in 
the Netherlands. In the United Kingdom, the study was approved by 
the Research Ethics Committee (NRES committee South Central—
Berkshire, REC reference 15/SC/0367); an opt- out consent procedure 
was used to collect anonymized clinical data.
2.2 | Methods
The following information was extracted from the medical notes: pa-
tient characteristics, including age, body weight, baseline FIX level and 
history of FIX neutralizing inhibiting antibodies; and surgical and treat-
ment characteristics that consisted of severity of surgical procedure 
(minor and major), mode of infusion (continuous and bolus infusion), 
type of product (recombinant and plasma- derived FIX concentrates), 
FIX concentrate infusion time and dose, and time of FIX level moni-
toring measured in IU mL−1. FIX levels were monitored daily and 
difference of 0.19 IU mL−1 [IQR 0.10- 0.39]. Clinically relevant bleeding complications 
(necessity of a second surgical intervention or red blood cell transfusion) occurred in 
7 procedures (2.7%).
Conclusion: This study demonstrates that targeting of FIX levels in the perioperative 
setting is complex and suboptimal, but although this bleeding is minimal. Alternative 
dosing strategies taking patient and surgical characteristics as well as pharmacoki-
netic principles into account may help to optimize and individualize treatment.
K E Y W O R D S
clotting factor concentrates, haemophilia B, haemostasis, individualized treatment, 
perioperative replacement therapy, surgical procedures
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measured by one- stage assays in participating centres according to 
local protocol. Bleeding complications were defined as need of a sec-
ond surgical intervention, haemoglobin decrease of >1.24 m molL−1 
(>20 g L−1) and/or red blood cell transfusion, or bleeding prolonging 
hospitalization, according to the International Society of Thrombosis 
and Haemostasis guidelines for major bleeding.7 Clinically relevant 
bleeding complications were defined as bleeding complications requir-
ing a second surgical intervention and/or necessity of a red blood cell 
transfusion. The duration of the perioperative period in the study was 
equivalent to duration of hospitalization (day of discharge minus day 
of surgery and start of infusion of FIX concentrates).
All patients received replacement therapy with FIX concentrate 
according to National and/or hospital guidelines with daily monitor-
ing of FIX, while aiming for target FIX levels as prescribed (Table 1).8 
Perioperative treatment in severe and moderate haemophilia B 
patients consisted of FIX bolus infusion of approximately 100 IU kg−1, 
followed by either continuous infusion or intermittent bolus infusions.8 
Only measured trough and steady- state FIX levels were compared to 
predefined FIX target ranges. Trough FIX levels were measured prior 
to next FIX bolus infusion, if treatment by bolus was performed. 
Steady- state FIX levels were defined as FIX levels measured when FIX 
concentrate substitution was equal to clearance in patients with treat-
ment by continuous infusion. In general, it is assumed that steady state 
is reached after a loading dose is administered and continuous infusion 
is started. FIX peak levels after FIX bolus infusions were not included 
in analysis of this data set. Low FIX levels were defined as all FIX levels 
below lowest predefined target range level. High FIX levels were de-
fined as all FIX levels above highest predefined target range level. FIX 
levels	with	a	difference	of	≥0.20	IU	mL−1 above the highest FIX target 
range were defined as excessively high. This cut- off of 0.20 IU mL−1 
was chosen arbitrarily to overcome inclusion of high FIX levels solely 
due to logistic delay of adjustment of treatment.
Potential predictors of FIX levels lower or higher than the tar-
get range were identified before analysis and based on the potential 
effects that they may have on PK parameters, eg clearance and/or 
volume of distribution of infused FIX concentrate. These consisted 
of age, body weight, history of FIX neutralizing inhibiting antibodies, 
type of product (recombinant or plasma- derived FIX), mode of infu-
sion (continuous or bolus infusion), severity of surgical procedure. 
Also the influence of a clinically relevant bleeding complication was 
evaluated. In calculations of total perioperative FIX consumption, only 
FIX concentrate administered during the hospitalization period and 
during first surgical procedure in each individual patient was included.
2.3 | Statistical analysis
The nonparametric Mann- Whitney U test was used for comparison of 
FIX consumption between groups. To evaluate trends in FIX consump-
tion, a “p for trend analysis by one- way ANOVA” was used. A stepwise 
forward and backward logistic regression analysis was performed to 
identify predictors of FIX levels lower or higher than target FIX lev-
els with elimination of variables with P > .10. A Pearson chi- squared 
test was used for comparisons between proportions. General char-
acteristics are presented as median and 25- 75% interquartile range 
(IQR) and as number and percentages for respectively continuous and 
categorical variables. Data management and statistical analysis were 
performed with SPSS for Windows, version 21.0 (SPSS Inc., Chicago, 
IL, USA). A P- value of <.05 was considered statistically significant.
3  | RESULTS
A total of 118 severe and moderate haemophilia B patients who un-
derwent a total of 255 surgical procedures were included. Of these, 85 
(72%) were severe haemophilia B patients, of which 36 were on prophy-
lactic treatment. Patient characteristics are shown in Table 2. Eighty- two 
adult patients underwent a total of 201 surgical procedures (median 
age 46 years; median body weight 85 kg), and 36 children underwent a 
TABLE  1 Specifications of perioperative replacement therapy 
according to guidelines, definition of bleeding complications and 
typical surgical procedures
Specified FIX target ranges in the perioperative perioda
Time 
FIX target level 
(IU mL−1)Day Hours
1 0- 24 0.80- 1.00
2- 5 24- 120 0.50- 0.80
	≥6 >120 0.30- 0.50
Definition of bleeding  
complicationsb
Definition of clinical 
relevant bleeding
Re- operation Re- operation
Red blood cell  
transfusion 
Red blood cell 
transfusion 
Haemoglobin drop  
>1.24 mmol L−1
Bleeding with prolonged  
hospitalization 
Examples of typical minor and major surgical procedures included 
in the studyc
Minor Major
Dental procedures  
or surgery
Total knee/ hip and 
shoulder 
replacement
Excision of lipoma Adenoid- 
tonsillectomy
Insertion/removal of  
intravenous catheters
Colorectal surgery
Vascular surgery
Maxillo- facial 
surgery (bimaxil-
lary osteotomy)
IU mL−1, International Units per milliliter.
aAccording to the National and/or hospital guidelines of the Netherlands 
and United Kingdom.
bAccording to the International Society of Thrombosis and Haemostasis.6
cAccording to the surgical risk score of Koshy et al4
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total of 54 surgical procedures (median age 6 years; median body weight 
19 kg). Twenty- six patients with 51 surgical procedures were included 
from Haemophilia Treatment Centres in the Netherlands and 92 patients 
with 204 surgical procedures from Haemophilia Treatment Centres in 
the United Kingdom. In children, 25 (46%) of all surgical procedures con-
sisted of an insertion or removal of a central intravenous catheter; adult 
patients underwent an orthopaedic surgical procedure most frequently 
(n = 92; 46%). Most patients (n = 199; 78%) received their replacement 
therapy by bolus infusion therapy. In 201 (79%) surgical procedures, pa-
tients were treated with recombinant factor concentrates. Children had a 
higher FIX consumption than adults (children: 145 IU kg−1 day−1 [IQR 71- 
234 IU kg−1 day−1]; adults: 68 IU kg−1 day−1 [IQR 34- 97 IU kg−1 day−1]; 
P < .001). In accordance with guidelines, FIX consumption was highest 
on day 1 in both adults and children. Strikingly, FIX consumption did not 
decrease as prescribed during hospitalization from day 2 until day 7 (P 
for trend = .92; Figure 1). Patients with a minor surgical procedure were 
admitted for a median of 3 days (IQR 25% and 75% range: 1- 5 days) and 
with a major surgical procedure for a median of 8 days (IQR 3- 13 days).
3.1 | Perioperative complications
In only 3 (1.2%) surgical procedures, clinically relevant bleeding 
complications were observed. Two of these 3 patients underwent 
total knee replacements followed by haemarthrosis requiring a sec-
ond intervention. One of these 3 patients received a red blood cell 
TABLE  2 General characteristics of study population
Total cohort Adults Children
No. (%); or Median [IQR]
Patient characteristics
No. of patients 118 82 36
Age (y) 40 [22- 58] 46 [34- 59] 6 [2- 11]
Body weight (kg) 79 [65- 92] 85 [73- 95] 19 [13- 39]
Severe haemophilia B 
(<0.01 IU mL−1)
85 (72) 57 (70) 28 (78)
On prophylaxis 36 (31) 28 (34) 8 (22)
Blood group Oa 33 (28) 24 (29) 9 (25)
Neutralizing 
antibodies 
(historically)
6 (5) 5 (6) 1 (3)
Chronic hepatitis C 47 (40) 46 (56) 1 (3)
Surgical characteristics
No. of surgical 
procedures
255 201 54
Total no. of patients undergoing
1 55 33 22
2 31 21 10
≥3 42 28 4
Major surgical 
procedure
120 (47) 105 (52) 15 (28)
Type of surgical procedure
General 19 (7) 16 (8) 3 (6)
Colo- rectal 16 (6) 14 (7) 2 (4)
Vascular 9 (4) 9 (4) 0 (0)
Cardio- thoracic 3 (1) 2 (1) 1 (2)
Orthopedic 99 (39) 92 (46) 7 (13)
Urological 11 (4) 11 (5) 0 (0)
Maxillofacial 1 (0) 1 (0) 0 (0)
Ear- Nose- Throat 9 (4) 5 (2) 4 (7)
Neurosurgery 1 (0) 1 (0) 0 (0)
Eye surgery 2 (1) 2 (1) 0 (0)
 (Re)placement 
central intrave-
nous catheters
27 (11) 2 (1) 25 (46)
Dental extractions 31 (12) 25 (12) 6 (11)
Miscellaneous 27 (11) 21 (10) 6 (11)
Replacement therapy with factor concentrate, hospitalization and 
blood loss
Mode of infusion
Continuous 56 (22) 54 (27) 2 (4)
Bolus 199 (78) 147 (73) 52 (96)
Total cohort Adults Children
No. (%); or Median [IQR]
Product type
Recombinantb 201 (79) 150 (75) 51 (91)
Plasma derivedc 54 (21) 51 (25) 3 (6)
Duration of 
hospitalization 
(days)
4 [2- 9] 5 [2- 11] 4 [2- 5]
Complications during perioperative period
No. of patients suffering from a complication
Bleeding
Re- operation 2 (2) 2 (2) 0 (0)
Haemoglobin drop 
>1.24 mmol L−1
23 (19) 17 (21) 6 (17)
Red blood cell 
transfusion
1 (1) 1 (1) 0 (0)
Thrombosis 0 (0) 0 (0) 0 (0)
No., number; IQR, inter- quartile range; kg, kilogram; IU mL−1, interna-
tional units per milliliter.
aBlood group available in 80 patients.
bIncluding BeneFix (Pfizer Wyeth Pharmaceuticals Inc., Kent, UK)
cIncluding AlphaNine (Grifols Biologicals Inc. Los Angeles, USA); Replenine 
(Bio Products Laboratory, Hertfordshire, UK); Haemonine (Biotest 
Pharma GmbH, Dreierich, Germany); Mononine (CSL Behring GmbH, 
Marbourg, Germany); Nonafact (Sanquin, Amsterdam, the Netherlands).
TABLE  2  (Continued)
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transfusion after surgery. No association between FIX levels and oc-
currence of a bleeding complication was found. However, FIX test-
ing was limited during bleeding events. No predictors of clinically 
relevant bleeding complications could be established.
3.2 | Observed FIX levels and comparison to 
target ranges
No differences were observed between observed FIX levels be-
tween treatment centres and between countries. Daily monitoring of 
FIX levels revealed that most perioperative FIX levels were outside 
specified target ranges (Figure 2). More specifically, 60% of trough or 
steady- state FIX levels were below target range with a median differ-
ence of 0.22 IU mL−1 [IQR 0.12- 0.36 IU mL−1] within 24 hours of the 
surgical procedure. Relative underdosing decreased over time with 
only 9% of values under target range at 6 days after surgery (median 
difference 0.09 IU mL−1 [IQR 0.05- 0.20 IU mL−1]). Conversely, an in-
crease in proportion of FIX levels above target range was observed 
over time, with 59% of FIX levels above target range with a median dif-
ference of 0.19 IU mL−1 [IQR 0.10- 0.39 IU mL−1] 6 days after surgery.
F IGURE  1 Perioperative FIX consumption on consecutive days. Overview of FIX consumption on consecutive postoperative days 
postoperatively. The amount of FIX administered factor concentrates was higher on day 1 in comparison with following days. P for trend 
analysis using one- way ANOVA showed no differences between amounts of FIX concentrates administered postoperatively
F IGURE  2 Achieved trough and steady- state FIX levels in the perioperative period. Achieved trough and steady- state FIX levels are 
shown for both patients treated by bolus infusion replacement therapy (blue) and by continuous infusion (red). Bolus infusion therapy was 
predictive of lower levels in the first 24 h after surgery in comparison with replacement therapy by continuous infusion. Frequency of lower 
and higher FIX levels than target range with median difference in IU mL−1 and corresponding 25- 75% interquartile range (IQR) during the 
perioperative period is shown corresponding to specified target ranges (green) as defined by National and/or hospital guidelines
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3.3 | Predictors of lower and higher FIX levels than 
target range
When analysing the complete perioperative period in the total study 
population, both treatments by bolus infusion and minor surgical pro-
cedures were predictive of lower FIX levels than required by guide-
lines (respectively, OR = 5.4 95% CI 3.5- 8.3, OR = 2.0 95% CI 1.2- 3.2). 
During the first 24 hours after surgery, only bolus infusion was pre-
dictive of lower FIX levels in comparison with continuous infusion 
(OR = 6.1 95% CI 2.8- 13.4; Table 3). Occurrence of a clinically rele-
vant bleeding complication and treatment with continuous infusion 
were	associated	with	excessively	high	FIX	levels	(≥0.20	IU	mL−1 above 
target). No differences were observed between achieved FIX levels 
between treatment centres or between countries and/or between 
product type (plasma derived versus recombinant) (data not shown).
4  | DISCUSSION AND CONCLUSION
This is the largest cohort of perioperative haemophilia B patients 
described to date with a total of 255 surgical procedures in 118 pa-
tients. This study demonstrates the challenges of perioperative FIX 
concentrate dosing as most perioperative FIX levels were outside 
the predefined target ranges recommended by National and/or hos-
pital guidelines. Importantly, 60% of trough and steady- state FIX 
levels were below the target level in the first 24 hours after surgery, 
while 59% of FIX levels were above target more than 6 days after 
surgery. Despite the lower FIX levels, clinically relevant bleeding 
complications were uncommon (3/255, 1.2%).
The lower FIX levels observed immediately after surgery 
in our study are most likely due to increased clearance of FIX 
concentrate during and directly after surgery 4 as well as in-
creased consumption of FIX due to activation of haemostasis by 
tissue damage and blood loss. Bolus infusion therapy was predic-
tive of FIX levels lower than target range, most prominently in 
the first 24 hours after surgery. This is in accordance with phar-
macokinetic principles as bolus infusions generally lead to overall 
lower trough levels when frequency of dosing is not sufficient. 
In addition, the somewhat higher FIX levels in patients treated 
by continuous infusion may be attributed to overall lower FIX 
clearance rates due to saturation of FIX binding sites and addi-
tional extravascular localization of FIX.5 Moreover, it should be 
considered that clinicians may have neglected to adapt continu-
ous infusion rates and may have tolerated or aimed for higher FIX 
levels in patients undergoing major surgical procedures. This is 
further supported by the observation, although not remarkable, 
that minor surgical procedures were predictive of underdosing, 
when the total perioperative period was evaluated. Minor sur-
gical procedures are often treated for a shorter period of time, 
with possible acceptance of lower FIX levels. Also, guidelines do 
not distinguish between severity of surgical procedure in haemo-
philia.8 Furthermore, as may be expected, patients with a clini-
cally relevant bleeding complication were excessively overdosed, 
due to repetitive bolus infusions and/or increased infusion rates 
in cases of continuous infusion.
4.1 | Study strengths and limitations
The large number of patients, 118 patients, and variety of surgical 
procedures, in total 255 from ten Academic Haemophilia Treatment 
Centres in two countries, make this study representative for peri-
operative management in high- income countries in severe and 
moderate- severe haemophilia B. Moreover, no differences were 
observed between observed FIX levels and FIX consumption be-
tween these treatment centres and between countries. Haemophilia 
B patients were treated in hospitals specialized in the treatment of 
patients with bleeding disorders. As such, there is experience of 
treating patients in the perioperative period with clotting factor 
concentrates. Moreover, these centres collaborate in international 
clinical and research networks and treat patients according to latest 
developments and standards. This study is one of the few studies 
evaluating perioperative management in haemophilia B with identifi-
cation of predictors of FIX levels lower and higher than target ranges 
specified by guidelines. Study limitations include the retrospective 
nature of the data. However, treatment characteristics, including 
FIX timing and dosing and timing of FIX sampling, were collected 
thoroughly, and complications were extensively documented. Yet, 
documentation of blood loss remained difficult, although we do feel 
that clinically relevant bleeding defined as necessity of a second sur-
gical intervention and/or necessity of a red blood cell transfusion 
depicts noteworthy bleeding in this cohort of perioperative patients. 
Patients with an established neutralizing antibody to FIX were ex-
cluded from analysis as these influence FIX clearance due to other 
immunological mechanisms. This study may lead to both refinements 
TABLE  3 Predictors of lower and (excessively) higher FIX levels 
than target rangea
OR 95% CI
Lower FIX levels (0- 24 h)
Bolus infusion (vs continuous) 6.1 2.8- 13.4
Age (increasing per year) 1.0 1.00- 1.03
Lower FIX levels (total perioperative period)
Minor surgical procedure (vs 
major)
2.0 1.2- 3.2
Bolus infusion (vs continuous) 5.4 3.5- 8.3
Age (increasing per year) 1.0 1.00- 1.02
Higher FIX levels
Continuous infusion (vs bolus) 3.1 2.2- 4.5
Age (decreasing per year) 1.0 1.0- 1.0
Excessively higher FIX levels
Continuous infusion (vs bolus) 1.6 1.03- 2.5
Bleeding complication (vs not 
present)
2.8 1.4- 5.8
OR, odds ratio; CI, confidence interval.
aStepwise forward and backward logistic regression analysis.
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of current guidelines with regard to target ranges as well as towards 
implementation of alternative dosing strategies based on more spe-
cific criteria than body weight and crude estimations of clearance, as 
the high proportion of FIX levels within 24 hours after surgery was 
not associated with a bleeding risk.
4.2 | Perioperative bleeding
Overall in our study population, perioperative bleeding in haemophilia 
B in both countries was rare (1.2%) and was not correlated with low 
FIX levels. However, FIX testing was limited during bleeding events. In 
literature, in 2 case series consisting of 36 and 25 surgical procedures 
respectively,4,5 higher percentages of clinically relevant bleeding 
events as defined in our study have been reported (4- 8.3%). In addi-
tion, most of these included patients underwent an orthopaedic surgi-
cal procedure. Contrastingly, in a cohort of 74 haemophilia B patients 
undergoing 81 surgical procedures, no red blood cell transfusions 
were reported and haemostatic efficacy was rated as excellent by 
surgical teams.9 In this study, also different minor and major surgical 
procedures were included, which was similar compared to our cohort. 
Exceptions are made for certain surgical procedures as a recent report 
by Kapadia et al showed that lower extremity total joint arthroplasty 
leads to significantly more red blood cell transfusions in haemophilia 
patients (15.1%) in comparison with a large matched cohort without a 
known bleeding history (9.8%); OR 1.60 (95% CI 1.11- 2.31).10
4.3 | Current guidelines and possible refinements
Although target ranges in most National and/or hospital guidelines 
do not differ between haemophilia A and B,8,11-13 other international 
guidelines such as set by the World Federation of Haemophilia (WFH) 
prescribe lower FIX levels in the perioperative setting.14 In contrast, in 
developing countries with scarce resources, even lower FIX levels are 
advised (FIX levels of 0.20- 0.50 for 1- 5 days postoperatively).14 A low 
frequency of perioperative bleeding under replacement therapy with 
lower FVIII and FIX target levels was reported by Srivastava et al in a 
single- centre respective study of 11 haemophilia A and 7 haemophilia B 
patients.15 In this study, FIX trough levels were set at 0.15- 0.30 IU mL−1 
on day 1- 3 postoperatively and at 0.10- 0.20 IU mL−1 more than 4 days 
postoperatively, until the wound had healed and sutures had been re-
moved. Only one of these 7 haemophilia B patients experienced post-
operative bleeds due to surgical reasons as verified by the surgeon. Our 
study supports these last findings, as in only 7 of 259 surgical proce-
dures (2.7%) a clinically relevant bleeding complication was documented 
despite underdosing within 24 hours after surgery in 60% of FIX levels. 
We conclude that there may be growing evidence that it may be pos-
sible to maintain lower FIX target ranges in the perioperative setting.
4.4 | Perioperative FIX consumption and 
individualization of therapy
Although a significant proportion of the study population were 
underdosed without bleeding, a significant proportion was 
overdosed, especially >6 days after surgery with 59% of trough 
and steady- state FIX levels above target. Current costs of health 
care for society warrant avoidance of excessive dosing without a 
clinical effect. Overdosing may be prevented by more individu-
alized dosing strategies that take patient, and surgical character-
istics as well as individual pharmacokinetics of concentrates into 
account.
Children had a higher FIX consumption when compared to 
adults, which is explained by a large volume of distribution and 
higher clearance.16
In prophylactic treatment, it has been proven that FIX consump-
tion can be significantly reduced by individualization of dosing based 
on pharmacokinetic modelling.17-20 Several studies have also shown 
that preoperative dosing based on an individual pharmacokinetic 
profile is safe, effective and applicable.5,21 However, the actual 
challenge is to implement iterative pharmacokinetic- guided FIX con-
centrate dosing during the perioperative period. This has not been 
possible to date, as a reliable perioperative population pharmaco-
kinetic model has been lacking. Widespread application of such a 
model will help to implement individualization of dosing, thereby in-
creasing the proportion of patients with FIX levels within the target 
range.
This study shows that targeting of FIX levels in the perioper-
ative setting is complex and results are suboptimal as both lower 
and higher levels than targeted are observed. Individualization 
of dosing by identification of predictors of volume of distribution 
and clearance of FIX concentrate may improve these outcomes. In 
addition, a critical assessment of current FIX target ranges seems 
warranted as few bleeding complications occurred in patients with 
lower levels than prescribed by National and/or hospital guidelines. 
Pharmacokinetic- guided dosing may help attain this goal, as lowering 
of FIX target ranges as set in such a study could be achieved reliably. 
Moreover, PK guidance may also decrease overdosing in the last days 
of the perioperative period. Therefore, we suggest that construc-
tion of population pharmacokinetic models and dosing according to 
these models will lead to more exact dosing in order to achieve FIX tar-
get ranges. Moreover, PK-guided dosing may be able to support studies 
aiming to refine and possibly lower current target ranges in haemo-
philia B, thus leading towards overall optimization of perioperative 
management in haemophilia B.
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